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A B S T R A C T
The administration of cryopreserved platelets (PLTs) may overcome the limits of platelet shortage and avail-
ability, especially during some seasons or in specific contexts like rural areas. After in vitro validation studies, ad
hoc prepared buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide
(DMSO) and cryopreserved (CRY BC-PLTs) at -80 °C with a modified Valeri method, were transfused in patients
with severe thrombocytopenia secondary to chemotherapy for acute leukaemia (AL). Five inpatients were en-
rolled in the pivotal clinical trial NCT02032134: 4 males and 1 female with a mean age of 71 years (range:
65–80). Four patients were diagnosed with acute myeloid leukaemia and 1 had acute lymphoblastic
leukaemia.Transfusion of one Unit of CRY BC-PLTs resulted effective in active bleeding control in two patients
without any adverse reaction or concomitant antihaemorrhagic therapies. CRY BC-PLTs met the currently ac-
cepted criteria for cryopreserved PLTs, their transfusion in patients with AL was safe. (Clinical trial:
NCT02032134).
1. Introduction
Platelet transfusion is frequently adopted for bleeding prophylaxis
in patients with blood cancer or severe thrombocytopenia secondary to
chemotherapies. Platelets are currently stored at room temperature
(RT, 20°C-24°C) under constant agitation, they can be administered
within 5 days after storage [1] according to current regulations. RT
stored PLTs are administered to increase the PLT count in thrombocy-
topenic patients and to prevent severe bleeding. The short shelf life and
agitation needed for RT PLT storage may however negatively impact
their use in some contexts like military and isolated fields [2,3]. Most of
the available in vivo studies on CRY-PLTs have been conducted on
healthy volunteers or trauma patients needing massive transfusions.
Studies on healthy volunteers showed a good viability of CRY-PLTs,
even if slightly reduced compared to liquid stored PLTs [4–6]. Clinical
studies on trauma patients requiring intensive transfusion support
mainly in the military field have not reported major adverse events with
improved overall survival and bleeding control [7]. Patients with
cancer and chemotherapy related thrombocytopenia are the largest
recipients of platelets; however, data on CRY-PLTs transfusion in these
subjects are scant [8–10]. Only one study has been performed in hae-
matological patients: autologous CRY-PLTs [9] treated with Throm-
boSol have been infused to control severe thrombocytopenia secondary
to chemotherapy. From this premise, after the development and in vitro
validation of a new kit for buffy coat derived platelet cryopreservation
(CRY BC-PLT) with DMSO [11], we have evaluated in the pilot in vivo
trial NCT02032134. the efficacy and safety of CRY BC-PLTs infused in
haematological cancer patients with severe thrombocytopenia
2. Methods
After in vitro assays determination of CRY BC-PLT viability up to 9
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months after storage, CRY BC-PLT concentrates for in vivo use were
prepared and handled with the same method adopted for the in vitro
study [11]. A patented cryopreservation kit has been adopted to avoid
one step of external manipulation of the BC-PLTs for cryopreservation.
Volunteer blood donors met the requirements of the Italian transfusion
centre’s recommendations and took no medication known to affect PLT
function for 10 days before donation. In detail, PLTs from 5 donors with
the same blood group were assembled in a sterile kit and mixed with an
InterSol solution (100mL) so that at least 30% was constituted by
plasma and 70% by InterSol. InterSol was adopted to wash the sacks
containing buffy coats and PLT outflow by increasing the volume of
supernatant for PLT suspension after centrifuge. The BC-PLTs combined
with InterSol underwent soft centrifugation and, with an automated
separator, were then leukoreduced with filtration. The PLT count was
assayed from the BC-PLTs after leukodepletion. BC-PLTs were selected
for storage only with a PLT count> 1250×103/μL. The final PLT
concentrates were transferred to a 650-mL patented cryopreservation
kit (Promedical). A total mean amount of 300mL BC-PLTs was then
transferred to one bag of the kit. After connecting a plastic bag con-
taining 75mL saline solution with 25% DMSO, under constant agita-
tion, the DMSO solution was transferred to the bag containing the BC-
PLTs in 5min. After mixing with the DMSO solution, each bag under-
went centrifugation (2000 g for 10min). Using a manual separator,
supernatant was then completely removed (leaving approximately 10 to
15mL) and the BC-PLTs were re-suspended with plasma from 1 of the
initial 5 PLT donors to a final volume of 200mL. The BC-PLTs rested for
approximately 45min, they were then agitated for approximately 1 h to
allow PLT disaggregation. CRY BC-PLTs were transfused in haemato-
logical in patients needing platelet transfusion for prophylaxis or
treatment of bleeding as referred in NCT02032134. The main objectives
of the trial were to evaluate the efficacy and safety of platelets, cryo-
preserved with DMSO by the above reported method, in patients with
severe thrombocytopenia. Haematological in-patients falling into one of
the following categories were eligible:: Stable clinical conditions and no
complications with platelets ≤ 10×109/L; active bleeding and
platelets ≤ 20× 109/L; high blood pressure, high fever, rapid drop in
platelets, infection, chemotherapy, coagulation abnormalities with
platelets ≤ 20×109/L. Patients suffering from congenital im-
munodeficiency, Hodgkin's disease treated with purine analogues
(Fludarabine, cladribine) and bone marrow transplant candidates, ei-
ther recipients or donors, were excluded.
To evaluate the availability of CRY-BC PLTs after transfusion, the
corrected count increment (CCI) of the platelets was determined at 1 h
and 24 h’ post-transfusion, respectively. CCI was determined according
to the following formula: (platelet increment per ul) x (body surface
area in m2)/number of platelets transfused (x 1011). Pre-treatment and
24 h after treatment, whole blood from patients transfused with CRY
BC-PLTs was tested for thromboelastography (TEG) and thrombin
generation potential (CAT). The patients were observed for up to 7 days
after infusion and the occurrence of any side effect was registered. The
study was carried out in accordance with the provisions of the
Declaration of Helsinki and local regulations. Informed consent was
obtained from each participant. The protocol was approved by the in-
stitutional review board at our institution and recorded on
ClinicalTrials.gov. Statistical analysis of quantitative and qualitative
data, including descriptive statistics, was performed for all the items.
Repeated measures analysis of variance (ANOVA) was adopted,
sphericity test [12] to determine the equality of variances of the dif-
ferences between measurements was also applied. Pairwise compar-
isons table was adopted to compare different measurements. Bonferroni
correction for multiple comparisons was applied for P-values and con-
fidence intervals. For P-value<0.05, it is concluded that there is a
significant difference between the different measurements. Data were
analysed using MedCalc Statistical Software version 14.8.1 (MedCalc
Software bvba, Ostend, Belgium).
3. Results
From June 2014 to January 2015, 5 inpatients were enrolled in
clinical trial NCT02032134: 4 males and 1 female (Table 1). with a
mean age of 71 years (range: 65–80). Four patients were diagnosed
with acute myeloid leukaemia (AML) and 1 had acute lymphoblastic
leukaemia (ALL). All enrolled patients received 1 unit (170–200mL
final volume) of CRY-BC PLTs: three patients were treated prophy-
lactically for very low PLT counts (mean basal PLT count= 5×109/L,
range: 2–7) secondary to chemotherapy; two patients had a very low
platelet count with active mucosal bleeding (epistaxis) at the time of
CRY BC-PLTs transfusion; four subjects had previusoly received, stan-
dard PLT concentrates from apheresis (mean PLT Units transfused in
each patient: 6, range:3-13) with a CCI of more than 10×109 /l (cal-
culated one hour after transfusion), after chemotherapy. Two patients,
aged 65 and 67 years, affected by AML were treated in induction with
cytarabine plus daunorubicin, one 77 years old patient with AML re-
ceived azacitidine, one 66 years old patient with ALL was treated with
cyclophosphamide and daunorubicin. All enrolled subjects were not
under any concomitant systemic anti-haemorrhagic treatment (such as
tranexamic acid) at the time of CRY-BC PLT transfusion. The mean
residual amount of DMSO in the CRY BC-PLTs was approximately
Table 1
Baseline characteristics of patients transfused with CRY BC-PLTs.
1* 2 3* 4* 5
Sex M F M M M
Age 67 77 66 65 80
Disease AML AML ALL AML AML
Reason for PLT transfusion Prophy Bleed Prophy Bleed Prophy
Basal PLT count (x 109/L) 4 7 6 6 2
PLT count (x 109/L) at 1 hour 8 7 21 6 3
PLT count (x 109/L) at 24 hours 12 4 17 6 2
CCI at 1 hour (x 109/L) 6800 0 5700 0 1700
CCI at 24 hours (x 109/L) 14400 0 18700 0 0
ALL= acute lymphoblastic leukaemia; AML= acute myeloid leukaemia;
CCI= corrected count increment; CRY BC-PLTs= cryopreserved buffy coat
derived platelets; F= female; M=male; PLT= platelets;
Prophy= prophylaxis; Bleed=mucosal bleeding (epistaxis). *Patients with
low platelet count secondary to chemotherapy.
Table 2
TEG parameters before and up to 24 h after infusion of CRY BC-PLTs.
T0
(N=5)
H1
(N=5)
H4
(N=5)
H24
(N=5)
P value
TEG-R (Mean ± SD) 17.68 ± 1.39 17.58 ± 2.31 16.50 ± 2.53 24.39 ± 1.85 NS
TEG-K (Mean ± SD) 27.63 ± 18.71 14.02 ± 0.90 25.58 ± 20.92 27.18 ± 12.5066 NS
TEG-MA (Mean ± SD) 36.08 ± 16.16 37.20 ± 14.17 27.45 ± 17.51 30.22 ± 17.31 NS
TEG-MRTG
(Mean ± SD)
11.46 ± 4.98 16.95 ± 3.42 13.53 ± 4.44 12.29 ± 4.31 NS
T0 = basal values before the infusion of 1 unit of CRY BC-PLTs; H1=1 h after infusion; H4=4 h after infusion; H24=24 h after infusion; TEG-MRTG=maximum
rate of thrombus generation; NS: Not significant.
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400mg per transfused unit. One patient showed a good response to the
CRY BC-PLTs with an increase in the PLT count after 1 h, stable up to
24 h (Table 1). Bleeding was effectively prevented in all cases. Epistaxis
ceased after CRY BC-PLT transfusion without any concomitant addi-
tional anti-haemorrhagic medication, even if thrombocytopenia was
not overcome. In detail, epistaxis was completely controlled within two
hours after CRY BC-PLTs transfusion, in both cases. Three patients
treated with CRY BC-PLT required also, on the same day, red bood cells
(RBC, 1U) transfusions for severe anemia. RBCs were given 12 h after
CRY BC-PLTs in all cases. One patient transfused with CRY BC-PLT for
Fig. 1. Thrombin generation curves before and 24 h after CRY BC-PLTs transfusion.
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epistaxis, had received RBC transfusion (1U), twenty-four hours before
CRY BC-PLTs. Fresh frozen plasma was not administered in any of the
enrolled patients at the time of CRY BC-PLTs and during the observa-
tion period. TEG parameters, assayed on whole blood, from baseline up
to 24 h after transfusion are illustrated in Table 2 (not statistically
significant difference was observed among the reported parameters).
Thrombin generation potential was stably maintained up to 24 h after
the infusion of 1 unit of CRY-BC PLTs without any adverse effect (mean
ETP pre-treatment was 414.13 ± 160.60, and 24 h after transfusion
was 326.95 ± 152.54). Fig. 1 illustrates CAT results from four enrolled
patients. CRY-BC PLTs could significantly decrease the time to clot
formation and clot strength as measured also by thromboelastography.
CRY-BC PLT activation/deterioration was accompanied by an effective
haemostatic in vivo function. The primary aim of the trial was to
evaluate the efficacy of CRY BC-PLTs (an increase in the platelet count
after transfusion); the trial was however terminated because of further
recruitment failure within the interval of available CRY BC-PLTs for the
study. CRY BC-PLT transfusion did not cause any adverse reaction,
acute or late.
4. Discussion
We have here transfused CRY BC PLTs in five patients with acute
leukaemia, the current study could thus be considered as a pivotal trial.
TEG on whole blood from patients transfused with CRY BC-PLTs was
also performed. The adequate haemostasis achieved at TEG in in vivo
studies supports the hypothesis that in vitro CRY BC-PLT activation/
deterioration does not necessarily mirror an impaired haemostatic in
vivo function. Storage-associated defects identified in vitro may be re-
versible upon transfusion [13]. In cases of massive or active bleeding,
the haemostatic function becomes essential to allow fast blood clot
formation. On a clinical point of view, haematologists on the contrary
ground the transfusion management of patients with severe thrombo-
cytopenia on the expected increase in PLTs count; platelet circulating
time is the first issue usually considered when administering PLTs
concentrates for prophylaxis, aiming to stably maintain a “safe” plate-
lets count value (PLTs>10×109/L). For the above reported expected
outcome, it was difficult to further enrol patients in the clinical trial
NCT02032134.We must however acknowledge that universally re-
cognised criteria for the transfusion of cryopreserved platelets are
currently lacking. The wide interindividual variability of global hae-
mostatic assay indicators and platelet characteristics might negatively
affect the clinical validity of laboratory assays performed on cryopre-
served products. Currently available assays have been often adopted to
evaluate only specific platelets properties such as recovery or survival,
but not for others such as haemostatic functions.
The post-transfusion effects of released platelet cytokines are still
uncertain and have been explored mainly in emergency settings. Our
clinical results, even if on a quite small number of subjects enrolled, in
part mirror those observed in the context of autologous CRY-PLT ad-
ministration in patients with severe thrombocytopenia secondary to
high-dose chemotherapy, where CRY-PLTs directly frozen at -80 °C did
not overcome thrombocytopenia [9].
In vivo recovery of cryopreserved platelets in thrombocytopenic
patients was half that of fresh platelets [8]. Similarly, CRY-PLT infu-
sions in cardiopulmonary surgery settings [14,15] showed a good
control of blood loss but lower post-transfusion increase in the PLT
count and impaired platelet survival. To the best of our knowledge, this
is the first prospective trial to evaluate the clinical efficacy and safety of
cryopreserved buffy coat-derived platelet transfusion in haematological
patients. Patients enrolled in the reported trial were frail subjects with
acute leukemia; however, they did not experience any immediate or
late adverse events secondary to transfusion. DMSO is infact known to
determine cardiac, neurological, and renal side effects [8] but CRY BC-
PLT units obtained with the previously reported method presented a
low final DMSO concentration, so they resulted safe and well tolerated.
Our findings do not allow any firm conclusion on the administration of
CRY BC-PLTs in haematological patients with acute leukaemia mainly
due to the small number of enrolled patients. The efficacy and safety of
CRY BC-PLTs in patients with acute leukaemia needs to be better as-
sessed in larger prospective ad hoc studies. Feasibility of CRY-BC-PLTs
also in haematological settings, besides military and trauma, may be of
great support.
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